Cerebral sinus venous thrombosis in a subject with thyrotoxicosis and MTHFR gene polymorphism

Neurological Sciences

Volumn 29, Issue 5, 2008, Pages 343-345

  Strada, Laura ^a   Gandolfo, Carlo ^a   Sette, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cerebral venous thrombosis; Heparin; Methylene tetrahydro folate reductase (MTHFR); Tyrotoxicosis; Warfarin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYTIDINE; FOLIC ACID; HEPARIN; OXCARBAZEPINE; PHENOBARBITAL; PYRIDOXINE; THIAMAZOLE; THYMIDINE; THYMOCYTE ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; VALPROIC ACID; WARFARIN;

ADULT; ANTIBODY TITER; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE REPORT; CEREBRAL SINUS THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EXOPHTHALMOS; FOCAL EPILEPSY; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; GRAVES DISEASE; HEADACHE; HEMIPARESIS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERHOMOCYSTEINEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SINUS TACHYCARDIA; SKIN ALLERGY; THYROID HORMONE BLOOD LEVEL; THYROTOXICOSIS; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; HEPARIN; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; SINUS THROMBOSIS, INTRACRANIAL; THYROTOXICOSIS; WARFARIN;

EID: 55649116875     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-0992-4     Document Type: Article

References (10)

1. Verberne HJ, Fliers E, Prummel MF et al (2000) Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis. Thyroid 10:607-610
2. Kasuga K, Naruse S, Umeda M et al (2006) Case of cerebral venous thrombosis due to Graves' disease with increased factor VIII activity. Rinsho Shinkeigaku 46:270-273
3. Nagumo K, Fukushima T, Takahashi H et al (2007) Thyroid crisis and protein C deficiency in a case of superior sagittal sinus thrombosis. Brain Nerve 59:271-276
4. Mouton S, Nighoghossian N, Berruyer M et al (2005) Hyperthyroidism and cerebral venous thrombosis. Eur Neurol 54:78-80
5. Squizzato A, Gerdes VE, Brandjes DP et al (2005) Thyroid diseases and cerebrovascular disease. Stroke 36:2302-2310
6. Hustad S, Nedrebo BG, Ueland PM et al (2004) Phenotypic expression of the methylenetetrahydrofolate reductase 677C→T polymorphism and flavin cofactor availability in thyroid dysfunction. Am J Clin Nutr 80:1050-1057
7. Shafqat S, Kamal AK, Wasay M (2006) Heparin in the treatment of cerebral venous thrombosis. J Pak Med Assoc 56:541-543
8. Einhäupl K, Bousser MG, de Bruijn SF et al (2006) EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 13:553-559
9. Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Circulation 113:409-449
10. Jukic I, Titlic M, Tonkic A, Rosenzweig D (2007) Cerebral venous sinus thrombosis as a recurrent thrombotic event in a patient with heterozygous prothrombin G20210A genotype after discontinuation of oral anticoagulation therapy: How long should we treat these patients with warfarin? J Thromb Thrombolysis 24:77-80